Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic disorders. These naturally occurring molecules are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 peptides demonstrate promising therapeutic outcomes in treat